Skip to main content

Hemolytic Disease of the Fetus and Newborn clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety in mother and neonate/infant of M281 administered to pregnant women who are at high risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN). The effectiveness of the investigational drug M281 will be measured by looking at the percentage of participants with live birth at or after gestational age (GA) 32 weeks and without a need for an intrauterine transfusion (IUT) throughout their entire pregnancy.

    San Francisco, California and other locations

Last updated: